Combigene has decided to carry through the bid to shareholders in Panion

Report this content

The shareholders of Panion Animal Health AB have accepted the offer from Combigene AB with an acceptance rate below 90%. The exact number is expected to be announced tomorrow the of July 2019.

Despite not reaching the intended 90% of acceptance and with reference to the press release from Combigene AB, link, Combigene’s board has decided to complete the bid and end the acceptance period and that the non-cash shares issue is carried out.

The board and management of Panion have noted the outcome of the procedure and will immediately consider and facilitate the necessary steps in the process for Panion.

Anja E. H. Holm, CEO
+ 45-22 94 66 00

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Documents & Links